Phospho-RPS6KA4 (T568) Antibody

What is RPS6KA4 and what cellular functions does it regulate?

RPS6KA4, also known as MSK2 (Mitogen and Stress-activated protein Kinase 2), is a serine/threonine protein kinase that plays critical roles in several cellular processes. It is a member of the ribosomal S6 kinase (RSK) family and contains two non-identical kinase catalytic domains . RPS6KA4/MSK2 functions in multiple signaling pathways including:

• Phosphorylation of transcription factors CREB1 and ATF1 in response to mitogenic or stress stimuli

• Regulation of transcription factor RELA

• Contribution to gene activation through histone phosphorylation, particularly histone H3-S10 and H3-S28

• Regulation of inflammatory genes and inflammatory responses

• Interleukin-1-mediated signaling pathway

• Positive regulation of NF-kappaB transcription factor activity

Understanding these pathways is essential for researchers interpreting results from experiments using phospho-specific antibodies targeting this protein.

What is the significance of T568 phosphorylation in RPS6KA4/MSK2?

The T568 (Threonine 568) phosphorylation site on RPS6KA4/MSK2 represents a specific post-translational modification that can indicate activation status of this kinase. While the search results don't provide explicit details on the exact role of T568 phosphorylation, the development of specific antibodies targeting this site suggests its importance in regulating MSK2 function .

Unlike better-characterized phosphorylation sites such as S247 in ribosomal protein S6 (which has been validated as an in vivo phosphorylation site ), T568 phosphorylation likely plays a regulatory role in MSK2 activation or substrate specificity. Researchers studying MSK2 signaling pathways should monitor this phosphorylation site to better understand kinase regulation in different cellular contexts.

How does RPS6KA4/MSK2 differ from other members of the ribosomal S6 kinase family?

RPS6KA4/MSK2 belongs to the RSK family but has distinct characteristics that differentiate it from other family members such as p70S6K (encoded by RPS6KB1):

• Structural features: RPS6KA4 contains two non-identical kinase catalytic domains, which allows for complex regulation and diverse substrate specificity

• Upstream regulation: While p70S6K is primarily regulated through the mTOR pathway, RPS6KA4/MSK2 responds to mitogen and stress stimuli through MAPK pathways

• Substrate specificity: RPS6KA4/MSK2 primarily phosphorylates transcription factors and histones, whereas p70S6K targets ribosomal protein S6 at sites Ser235, Ser236, Ser240, and Ser244

• Cellular localization: RPS6KA4/MSK2 can be found in both cytoplasmic and nuclear compartments, with significant functions occurring in the nucleus for transcriptional regulation

These differences are important for researchers to consider when selecting appropriate antibodies and designing experiments to study specific RSK family members.

What are the recommended applications for Phospho-RPS6KA4 (T568) antibodies?

Based on manufacturer specifications and validation data, Phospho-RPS6KA4 (T568) antibodies are suitable for several experimental applications:

The antibody specifically detects endogenous levels of human RPS6KA4 only when phosphorylated at threonine 568 . It has been validated to react with both human and mouse samples , making it suitable for comparative studies across these species.

What controls should be included when using Phospho-RPS6KA4 (T568) antibodies?

To ensure experimental validity when using Phospho-RPS6KA4 (T568) antibodies, researchers should include the following controls:

• Positive control: Cell lysates from cells treated with agents known to induce T568 phosphorylation. While specific inducers for T568 phosphorylation aren't mentioned in the search results, PMA (phorbol 12-myristate 13-acetate) treatment has been shown to induce phosphorylation of related proteins and may serve as a starting point.

• Negative control:

  • Cell lysates treated with phosphatase to remove phosphorylation

  • Cell lysates treated with kinase inhibitors that block the relevant pathways

  • Lysates from cells treated with LY294002 (PI3K inhibitor) may serve as negative controls, as shown in related phospho-protein detection systems

• Specificity control:

  • If available, use cells expressing RPS6KA4 with T568A mutation

  • Pre-absorption of antibody with the immunizing phosphopeptide

• Loading control: Detection of total RPS6KA4 (using a phosphorylation-independent antibody) to normalize phospho-signal to total protein levels

These controls are critical for confirming antibody specificity and ensuring accurate interpretation of experimental results.

What is the recommended protocol for detecting phospho-RPS6KA4 (T568) by Western blotting?

While specific protocols for phospho-RPS6KA4 (T568) detection were not provided in the search results, the following optimized Western blot protocol can be derived from standard practices for phospho-specific antibodies:

• Sample preparation:

  • Harvest cells in phosphatase inhibitor-containing lysis buffer to prevent dephosphorylation

  • Include protease inhibitors to prevent protein degradation

  • Use buffer containing 50 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, with phosphatase inhibitors (sodium fluoride, sodium orthovanadate, β-glycerophosphate)

• Electrophoresis and transfer:

  • Resolve 20-40 μg of protein using 10% SDS-PAGE

  • Transfer to PVDF membrane (recommended over nitrocellulose for phospho-proteins)

• Antibody incubation:

  • Block membrane with 5% BSA in TBST (not milk, which contains phosphatases)

  • Incubate with phospho-RPS6KA4 (T568) antibody at dilution of 1:500-1:2000 in 5% BSA-TBST overnight at 4°C

  • Wash 3x with TBST

  • Incubate with HRP-conjugated secondary antibody (anti-rabbit) at 1:5000 in 5% BSA-TBST for 1 hour at room temperature

• Detection:

  • Develop using enhanced chemiluminescence (ECL) substrate

  • For quantitative analysis, consider using fluorescent secondary antibodies and imaging systems

• Stripping and reprobing:

  • Strip and reprobe membrane with total RPS6KA4 antibody to normalize phospho-signal

This protocol should be optimized for specific experimental conditions and cell types.

How can I validate the specificity of phospho-RPS6KA4 (T568) signal in my experiments?

Validating specificity is crucial when working with phospho-specific antibodies. For phospho-RPS6KA4 (T568), consider these approaches:

• Phosphatase treatment: Treat half of your sample with lambda phosphatase before Western blotting. The phospho-specific signal should disappear in the treated sample while total RPS6KA4 signal remains unchanged.

• Stimulation/inhibition experiments:

  • Treat cells with known activators of MAPK pathways, which should increase T568 phosphorylation

  • Treat cells with pathway inhibitors to reduce phosphorylation

• siRNA/shRNA knockdown: Reduce RPS6KA4 expression with siRNA or shRNA. Both phospho and total signals should decrease proportionally.

• Peptide competition: Pre-incubate antibody with the immunizing phosphopeptide before Western blotting. The specific signal should be blocked.

• Site-directed mutagenesis: If possible, express wild-type RPS6KA4 and T568A mutant in cells. The phospho-antibody should detect only the wild-type protein.

These validation strategies help ensure that the observed signals truly represent phosphorylated RPS6KA4 at T568, rather than cross-reactivity with other phospho-proteins.

What are common issues when detecting phospho-RPS6KA4 (T568) and how can they be addressed?

When working with phospho-RPS6KA4 (T568) antibodies, researchers may encounter these common challenges:

For optimal results with phospho-RPS6KA4 (T568) antibodies, carefully control experimental conditions and include appropriate controls to validate specificity.

How do I interpret changes in RPS6KA4 T568 phosphorylation in relation to total protein levels?

Proper interpretation of phosphorylation changes requires consideration of total protein levels and experimental context:

• Normalize phospho-signal to total protein: Always detect both phosphorylated and total RPS6KA4 in parallel to calculate the phospho/total ratio, which represents the proportion of phosphorylated protein.

• Consider these scenarios:

  • Increased phospho/total ratio: Enhanced kinase activity targeting T568

  • Decreased phospho/total ratio: Reduced kinase activity or enhanced phosphatase activity

  • Unchanged phospho/total ratio with increased total protein: Proportional increase in phosphorylation

  • Unchanged phospho/total ratio with decreased total protein: Proportional decrease in phosphorylation

• Context-dependent interpretation:

  • Acute stimuli (minutes to hours): Changes in phosphorylation without changes in total protein likely reflect direct regulation of kinase/phosphatase activity

  • Chronic treatments (hours to days): May affect both phosphorylation and protein expression levels

• Consider pathway cross-talk: Changes in T568 phosphorylation may reflect regulation from multiple upstream pathways, not just a single kinase or stimulus.

For comprehensive understanding, examine phosphorylation at multiple sites on RPS6KA4 and investigate both upstream regulators and downstream targets.

How can I use phospho-RPS6KA4 (T568) antibodies to study cross-talk between signaling pathways?

Investigating signaling cross-talk using phospho-RPS6KA4 (T568) antibodies requires sophisticated experimental designs:

• Combinatorial stimulation/inhibition:

  • Apply combinations of stimuli that activate different upstream pathways

  • Use pathway-specific inhibitors to dissect contributions from each pathway

  • Measure T568 phosphorylation levels to identify additive, synergistic, or antagonistic effects

• Time-course experiments:

  • Analyze T568 phosphorylation at multiple time points after stimulation

  • Compare kinetics across different stimuli and cell types

  • Identify delayed or sustained phosphorylation indicating indirect regulation

• Multi-site phosphorylation analysis:

  • Compare phosphorylation patterns across multiple sites on RPS6KA4/MSK2

  • Investigate how different stimuli affect site-specific phosphorylation

  • Analyze correlation between phosphorylation at T568 and other sites

• Integrative approaches:

  • Combine phospho-specific detection with activity assays to correlate T568 phosphorylation with kinase activity

  • Use proximity ligation assays to detect interactions between phospho-RPS6KA4 and upstream kinases or downstream substrates

These approaches can reveal how T568 phosphorylation integrates signals from multiple pathways and contributes to downstream responses.

What are the differences in detecting RPS6KA4 T568 phosphorylation versus other phosphorylation sites in the RSK family?

Differential detection of phosphorylation sites across the RSK family presents unique considerations:

• Site-specific contexts:

  • T568 in RPS6KA4/MSK2 likely has a different structural and functional context than analogous sites in other RSK family members

  • Phosphorylation at sites like Ser240/244 in ribosomal protein S6 (a downstream target of RSK) is linked to mitogen-dependent translation regulation

  • Ser247 in ribosomal protein S6 has been validated as an in vivo phosphorylation site using phospho-specific antibodies

• Technical considerations:

  • Different phospho-sites may require site-specific sample preparation methods

  • The optimal antibody dilution ranges vary across phospho-sites (for example, 1:500-1:2000 for phospho-RPS6KA4 T568 in Western blot versus other dilutions for different sites)

  • Some phospho-sites may be more labile than others during sample processing

• Pathway-specific regulation:

  • T568 phosphorylation in RPS6KA4/MSK2 likely responds to different stimuli compared to analogous sites in other RSK family members

  • While p70S6K phosphorylates S6RP in a mitogen-dependent fashion , MSK2 regulation may involve both mitogenic and stress stimuli

• Validation strategies:

  • Each phospho-site requires specific positive controls (such as PMA for some sites )

  • Mutation-based validation approaches need to be tailored to each specific site

Understanding these differences is crucial for researchers studying multiple phosphorylation events across the RSK family.

How can I use phospho-RPS6KA4 (T568) antibodies in multiplexed detection systems?

Multiplexed detection of phospho-RPS6KA4 (T568) alongside other signaling proteins enables comprehensive pathway analysis:

• Multi-color immunofluorescence:

  • Use spectrally distinct fluorophores for different targets

  • Combine phospho-RPS6KA4 (T568) detection with markers of subcellular compartments

  • Analyze co-localization with upstream kinases or downstream substrates

• Multiplexed Western blotting:

  • Use differently sized targets on the same blot

  • Apply fluorescent secondary antibodies with different emission spectra

  • Sequential detection of phospho- and total-proteins on the same membrane

• Bead-based multiplex assays:

  • Adapt ELISA protocols (1:5000-1:40000 dilution ) to bead-based platforms

  • Simultaneously detect multiple phospho-proteins from the same sample

  • Compare phosphorylation patterns across different signaling nodes

• Specialized platforms:

  • MSD (Meso Scale Discovery) technology allows sensitive detection of phospho-proteins using electrochemiluminescence

  • These platforms can provide quantitative measures comparable to traditional Western blots but with higher throughput

• Phospho-proteomics integration:

  • Use phospho-RPS6KA4 (T568) antibodies for immunoprecipitation before mass spectrometry

  • Enrich phosphorylated RPS6KA4 to identify associated proteins or additional modification sites

These multiplexed approaches provide richer context for understanding the role of T568 phosphorylation in signaling networks.

What emerging technologies might enhance detection of phospho-RPS6KA4 (T568)?

Several cutting-edge technologies hold promise for advancing phospho-RPS6KA4 (T568) research:

• Single-cell phospho-protein analysis:

  • Mass cytometry (CyTOF) adapted for phospho-RPS6KA4 detection

  • Microfluidic platforms for single-cell Western blotting

  • These approaches would reveal cell-to-cell heterogeneity in T568 phosphorylation

• Live-cell biosensors:

  • FRET-based sensors to monitor RPS6KA4 phosphorylation in real-time

  • Phospho-specific nanobodies for intracellular tracking

  • These tools would provide temporal resolution of phosphorylation dynamics

• Spatial proteomics:

  • Imaging mass spectrometry to map RPS6KA4 phosphorylation across tissue sections

  • Highly multiplexed imaging techniques (e.g., CODEX, 4i) for simultaneous detection of multiple phospho-proteins

  • These methods would reveal spatial relationships between T568 phosphorylation and tissue architecture

• Advanced computational approaches:

  • Machine learning algorithms for automated quantification of phospho-signals

  • Network modeling to predict T568 phosphorylation based on upstream pathway activities

  • These computational tools would help integrate phospho-RPS6KA4 data into broader signaling networks

These emerging technologies could overcome current limitations in sensitivity, specificity, and temporal-spatial resolution of phospho-RPS6KA4 detection.

How might phospho-RPS6KA4 (T568) analysis contribute to understanding disease mechanisms?

Investigating phospho-RPS6KA4 (T568) in disease contexts could yield valuable insights:

• Cancer biology:

  • Aberrant RPS6KA4/MSK2 signaling may contribute to dysregulated gene expression in cancer

  • T568 phosphorylation status could serve as a biomarker for pathway activation

  • Correlation between T568 phosphorylation and response to kinase inhibitor therapies could inform personalized medicine approaches

• Inflammatory disorders:

  • Given RPS6KA4's role in inflammatory responses and regulation of NF-κB activity , T568 phosphorylation may be altered in inflammatory diseases

  • Monitoring T568 phosphorylation could provide mechanistic insights into inflammatory pathway activation

• Neurological conditions:

  • RPS6KA4/MSK2 functions in the regulation of CREB transcription factor activity , which is important for neuronal plasticity

  • Changes in T568 phosphorylation could be relevant in neurological disorders involving dysregulated CREB signaling

• Drug discovery applications:

  • Phospho-RPS6KA4 (T568) antibodies could be used in high-throughput screens for compounds that modulate this signaling node

  • Understanding the relationship between T568 phosphorylation and RPS6KA4 activity could inform development of specific inhibitors

These disease-focused applications highlight the translational potential of basic research on RPS6KA4 phosphorylation.

What are the current limitations in our understanding of T568 phosphorylation in RPS6KA4 function?

Despite available antibody tools, several knowledge gaps remain regarding T568 phosphorylation:

• Regulatory mechanisms:

  • The upstream kinase(s) responsible for T568 phosphorylation remain unclear

  • The stimuli that specifically induce or suppress T568 phosphorylation need further characterization

  • The relationship between T568 phosphorylation and RPS6KA4 catalytic activity requires clarification

• Functional consequences:

  • How T568 phosphorylation affects substrate specificity of RPS6KA4

  • Whether T568 phosphorylation influences RPS6KA4 subcellular localization

  • The temporal dynamics of T568 phosphorylation relative to other regulatory modifications

• Structural implications:

  • The three-dimensional context of T568 in the protein structure

  • How T568 phosphorylation might induce conformational changes

  • Potential for T568 phosphorylation to create or disrupt protein-protein interaction interfaces

• Physiological significance:

  • The phenotypic consequences of preventing T568 phosphorylation (e.g., through T568A mutation)

  • The role of T568 phosphorylation in different tissues and developmental stages

  • Conservation and divergence of T568 regulation across species

Addressing these knowledge gaps represents fertile ground for future research using phospho-RPS6KA4 (T568) antibodies and complementary approaches.